Molecular Profile | ERBB2 amp |
Therapy | Pertuzumab |
Indication/Tumor Type | colorectal cancer |
Response Type | no benefit |
Create By | spatt |
Update By | spatt |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | ERBB2 amp | colorectal cancer | no benefit | Pertuzumab | Preclinical - Pdx | Actionable | In a preclinical study, Perjeta (pertuzumab) did not inhibit tumor growth in patient-derived xenograft (PDX) models of ERBB2 (HER2)-amplified colorectal cancer (PMID: 22586653). | 22586653 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(22586653) | A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. | Full reference... |